Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Ophthalmology and Therapy
Published in: Ophthalmology and Therapy 1/2020

Open Access 01-03-2020 | Practical Approach

Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach

Authors: Anne-Sofie Petri, Kirstine Boysen, Lasse J. Cehofski, Elon H. C. van Dijk, Chantal Dysli, Josefine Fuchs, Rodolfo Mastropasqua, Yousif Subhi

Published in: Ophthalmology and Therapy | Issue 1/2020

Login to get access

Abstract

Intravitreal injections with vascular endothelial growth factor inhibitors constitute the most prevalent ophthalmic procedure in developed countries. Historically, there has been steady growth in the number of treatments performed of this kind, and projection studies estimate further growth in such treatments in the future. We provide a practical approach to intravitreal injections and discuss important aspects relating to the setting, the patient, the procedure, and the information given to the patient.
Literature
1.
Ohm J. Über die Behandlung der Netzhautablösung durch operative Entleerung der subretinalen Flüssigkeit und Einspritzung von Luft in den Glaskörper. Graefes Arch Ophthalmol. 1911;79:442–50.CrossRef
2.
Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina. 2009;29:875–912.PubMedCrossRef
3.
Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574–84.PubMedPubMedCentral
4.
Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–7.PubMedCrossRef
5.
Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221–34.PubMedCrossRef
6.
Cehofski LJ, Honoré B, Vorum H. A review: proteomics in retinal artery occlusion, retinal vein occlusion, diabetic retinopathy and acquired macular disorders. Int J Mol Sci. 2017;18:E907.PubMedCrossRef
7.
8.
Hollingworth W, Jones T, Reeves BC, Peto T. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015. BMJ Open. 2017;7:e018289.PubMedPubMedCentralCrossRef
9.
Saaddine JB, Honeycutt AA, Narayan KM, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Arch Ophthalmol. 2008;126:1740–7.PubMedCrossRef
10.
Ansah JP, Koh V, de Korne DF, et al. Projection of eye disease burden in Singapore. Ann Acad Med Singapore. 2018;47:13–28.PubMed
11.
Sedeh FB, Scott DAR, Subhi Y, Sørensen TL. Prevalence of neovascular age-related macular degeneration and geographic atrophy in Denmark. Dan Med J. 2017;64:A5422.PubMed
12.
Stockwell RE, Ballard EL, O’Rourke P, Knibbs LD, Morawska L, Bell SC. Indoor hospital air and the impact of ventilation on bioaerosols: a systematic review. J Hosp Infect. 2019;103:175–84.PubMedCrossRef
13.
Michels S, Becker M, Wachtlin J, Binder S. The intravitreal injection: variations in regulations, cost and reimbursement in Europe. Spektrum Augenheilkd. 2012;26:2.CrossRef
14.
15.
Samia-Aly E, Cassels-Brown A, Morris DS, Stancliffe R, Somner JE. A survey of UK practice patterns in the delivery of intravitreal injections. Ophthalmic Physiol Opt. 2015;35:450–4.PubMedCrossRef
16.
Subhi Y, Sørensen TL. Neovascular age-related macular degeneration in the very old (≥ 90 years): epidemiology, adherence to treatment, and comparison of efficacy. J Ophthalmol. 2017;2017:7194927.PubMedPubMedCentralCrossRef
17.
Casparis H, Wolfensberger TJ, Becker M, et al. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. Retina. 2014;34:12–7.PubMedCrossRef
18.
Brynskov T, Kemp H, Sørensen TL. No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. Retina. 2014;34:951–7.PubMedCrossRef
19.
Freiberg FJ, Brynskov T, Munk MR, et al. Low endophthalmitis rates after intravitreal anti-vascular endothelial growth factor injections in an operation room: a retrospective multicenter study. Retina. 2017;37:2341–6.PubMedCrossRef
20.
Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145:879–82.PubMedCrossRef
21.
Meredith TA, McCannel CA, Barr C, et al. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2015;122:817–21.PubMedCrossRef
22.
Rayess N, Rahimy E, Storey P, et al. Postinjection endophthalmitis rates and characteristics following intravitreal bevacizumab, ranibizumab, and aflibercept. Am J Ophthalmol. 2016;165:88–93.PubMedCrossRef
23.
Abell RG, Kerr NM, Allen P, Vote BJ. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol. 2012;96:1474–8.PubMedCrossRef
24.
Dossarps D, Bron AM, Koehrer P, Aho-Glélé LS, Creuzot-Garcher C, FRCR net (FRenCh Retina specialists net). Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome. Am J Ophthalmol. 2015;160:17–25e1.
25.
Bande MF, Mansilla R, Pata MP, et al. Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: a systematic review and meta-analysis. Sci Rep. 2017;7:18088.PubMedPubMedCentralCrossRef
26.
Rodríguez Ramírez M, del Barrio Manso MI, Martín Sánchez MD. Intravitreal injections: what do patients prefer? Analysis of patient’s satisfaction and preferences about where to perform intravitreal injections. Arch Soc Esp Oftalmol. 2014;89:477–83.PubMedCrossRef
27.
Rasul A, Subhi Y, Sørensen TL, Munch IC. Non-physician delivered intravitreal injection service is feasible and safe—a systematic review. Dan Med J. 2016;63:A5229.PubMed
28.
Hasler PW, Bloch SB, Villumsen J, Fuchs J, Lund-Andersen H, Larsen M. Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting. Acta Ophthalmol. 2015;93:122–5.PubMedCrossRef
29.
Chakouri S, Mundt LP, Subhi Y, Sørensen TL. Physician assistants and nurse practitioners in ophthalmology—has the time come? Am J Ophthalmol. 2018;186:174–5.
30.
31.
32.
Samalia P, Garland D, Squirrell D. Nurse specialists for the administration of anti-vascular endothelial growth factor intravitreal injections. N Z Med J. 2016;129:32–8.PubMed
33.
Hovaghimian DG, Adel SS. A novel multifunctional, intravitreal injection assistant: evaluation and comparison with conventional technique. J Egypt Ophthalmol Soc. 2016;109:122–34.CrossRef
34.
Gomez J, Koozekanani DD, Feng AZ, et al. Strategies for improving patient comfort during intravitreal injections: results from a survey-based study. Ophthalmol Ther. 2016;5:183–90.PubMedPubMedCentralCrossRef
35.
Chen X, Seth RK, Rao VS, Huang JJ, Adelman RA. Effects of music therapy on intravitreal injections: a randomized clinical trial. J Ocul Pharmacol Ther. 2012;28:414–9.PubMedCrossRef
36.
Jandorf S, Krogh Nielsen M, Sørensen TL. Irrigating the eye after intravitreal injection reduces epithelial damage but not patient discomfort. Acta Ophthalmol. 2019;97:e670–1.PubMedCrossRef
37.
Yang Y, Downew L, Mehta H, et al. Resource use and real-world outcomes for ranibizumab treat and extend for neovascular age-related macular degeneration in the UK: interim results from TERRA. Ophthalmol Ther. 2017;6(1):175–86.PubMedPubMedCentralCrossRef
38.
Grzybowski A, Told R, Sacu S, et al. 2018 update on intravitreal injections: Euretina Expert Consensus Recommendations. Ophthalmologica. 2018;239:181–93.
39.
Prabakaran SL, Eaton AM, Wafapoor H. Changes in intraocular pressure after intravitreal injection of bevacizumab (Avastin) and ranibizumab (Lucentis). Invest Ophthalmol Vis Sci. 2008;49:2101.
40.
Bach A, Filipowicz A, Gold AS, Latiff A, Murray TG. Paracentesis following intravitreal drug injections in maintaining physiologic ocular perfusion pressure. Int J Ophthalmol. 2017;10:1925–7.PubMedPubMedCentral
41.
Avery RL, Castellarin AA, Steinle NC, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab and ranibizumab. Retina. 2017;37:1847–58.PubMedPubMedCentralCrossRef
42.
Rim TH, Lee CS, Lee SC, Kim DW, Kim SS. Intravitreal ranibizumab therapy for neovascular age-related macular degeneration and the risk of stroke: a national sample cohort study. Retina. 2016;36:2166–74.PubMedCrossRef
43.
Zarbin MA, Francom S, Grzeschik S, et al. Systemic safety in ranibizumab-treated patients with neovascular age-related macular degeneration: a patient-level pooled analysis. Ophthalmol Retina. 2018;2:1087–96.PubMedCrossRef
44.
45.
Thulliez M, Angoulvant D, Pisella PJ, Bejan-Angoulvant T. Overview of systematic reviews and meta-analyses on systemic adverse events associated with intravitreal anti-vascular endothelial growth factor medication use. JAMA Ophthalmol. 2018;136:557–66.PubMedCrossRef
46.
Bressler NM, Boyer DS, Williams DF, et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina. 2012;32:1821–8.PubMedCrossRef
47.
Zarbin MA. Anti-VEGF agents and the risk of arteriothrombotic events. Asia Pac J Ophthalmol (Phila). 2018;7:63–7.
48.
49.
50.
Peracha ZH, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy in pregnancy: what we know, what we don’t know, and what we don’t know we don’t know. Retina. 2016;36:1413–7.PubMedCrossRef
51.
Bamdad S, Bamdad M, Khanlari M, Daneshbod Y, Khademi B. Teratogenic effects of intravitreal injection of bevacizumab in a pregnant rat model. Iran J Pharm Res. 2017;16:670–6.PubMedPubMedCentral
52.
McFarland TJ, Rhoads AD, Hartzell M, Emerson GG, Bhavsar AR, Stout JT. Bevacizumab levels in breast milk after long-term intravitreal injections. Retina. 2015;35:1670–3.PubMedCrossRef
53.
Concillado M, Lund-Andersen H, Mathiesen ER, Larsen M. Dexamethasone intravitreal implant for diabetic macular edema during pregnancy. Am J Ophthalmol. 2016;165:7–15.PubMedCrossRef
54.
Juncal VR, Francisconi CLM, Altomare F, et al. Same-day bilateral intravitreal anti-vascular endothelial growth factor injections: experience of a large Canadian retina center. Ophthalmologica. 2019;242:1–7.
55.
Yu CQ, Ta CN. Prevention and treatment of injection-related endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2014;252:1027–31.PubMedCrossRef
56.
Lau PE, Jenkins KS, Layton CJ. Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections. J Ophthalmol. 2018;2018:8567912.PubMedPubMedCentral
57.
58.
Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119(8):1609–14.PubMedCrossRef
59.
Shiroma HF, Takaschima AKK, Farah ME, et al. Patient pain during intravitreal injections under topical anesthesia: a systematic review. Int J Retina Vitreous. 2017;3:23.PubMedPubMedCentralCrossRef
60.
Friedman DA, Mason JO 3rd, Emond T, McGwin G Jr. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina. 2013;33(5):975–81.PubMedCrossRef
61.
Benoist d’Azy C, Pereira B, Naughton G, Chiambaretta F, Dutheil F. Antibioprophylaxis in prevention of endophthalmitis in intravitreal injection: a systematic review and meta-analysis. PLoS One. 2016;11:e0156431.
62.
Storey P, Dollin M, Rayess N, et al. The effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection. Graefes Arch Clin Exp Ophthalmol. 2016;254:235–42.PubMedCrossRef
63.
Reibaldi M, Pulvirenti A, Avitabile T, et al. Pooled estimates of incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents with and without topical antibiotic prophylaxis. Retina. 2018;38:1–11.PubMedCrossRef
64.
Loureiro M, Matos R, Sepulveda P, Meira D. Intravitreal injections of bevacizumab: the impact of needle size in intraocular pressure and pain. J Curr Glaucoma Pract. 2017;11:38–41.PubMedPubMedCentralCrossRef
65.
Haas P, Falkner-Radler C, Wimpissinger B, Malina M, Binder S. Needle size in intravitreal injections—pain evaluation of a randomized clinical trial. Acta Ophthalmol. 2016;94:198–202.PubMedCrossRef
66.
Pang CE, Mrejen S, Hoang QV, Sorenson JA, Freund KB. Association between needle size, postinjection reflux, and intraocular pressure spikes after intravitreal injections. Retina. 2015;35:1401–6.PubMedCrossRef
67.
68.
Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–16.PubMedCrossRef
69.
Jandorf S, Krogh Nielsen M, Sørensen K, Sørensen TL. Low health literacy levels in patients with chronic retinal disease. BMC Ophthalmol. 2019;19:174.PubMedPubMedCentralCrossRef
70.
Metadata
Title
Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach
Authors
Anne-Sofie Petri
Kirstine Boysen
Lasse J. Cehofski
Elon H. C. van Dijk
Chantal Dysli
Josefine Fuchs
Rodolfo Mastropasqua
Yousif Subhi
Publication date
01-03-2020
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 1/2020
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-020-00230-4

Other articles of this Issue 1/2020

Ophthalmology and Therapy 1/2020 Go to the issue

Practical Approach

Management Issues in Conjunctival Tumours: Ocular Surface Squamous Neoplasia

Review

Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review

Original Research

Intraocular Pressure Measurement with Pneumatonometry and a Tonometer Tip Cover

Original Research

A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration

Brief Report

Scleral Fixation of the Fluocinolone Acetonide Implant in Eyes with Severe Iris–Lens Diaphragm Disruption and Recalcitrant CME: The Fluocinolone-Loop-Anchoring Technique (FLAT)

Commentary

Open-Angle Glaucoma: Burden of Illness, Current Therapies, and the Management of Nocturnal IOP Variation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits